Ultimately, dihydroartemisinin prevents tumor immune escape by inhibiting the TGF-β, PI3K/Akt, and STAT3 signaling pathways to promote tumor eradication (Zhang E. et al., 2020; Zhang H. et al., 2020). The gene discussed is TGFB1; the disease is neoplasm.